HLN vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 22, 2026
HLN
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | HLN | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 15.6986 | 9.7656 | GSK |
| PEG Ratio | 2.151 | 6.1023 | HLN |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2.2% | 5.3% | GSK |
| Earnings Growth | -4.5% | -69.5% | HLN |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 24.7/100 | 37.4/100 | GSK |
| Profit Margin | 14.5% | 14.5% | HLN |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG SELL | AVOID NEW MONEY | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
HLN
NeutralMixed signals - no dominant trend phase, RSI 72
GSK
NeutralMixed signals - no dominant trend phase, RSI 63
Fundamentals Snapshot
| Metric | HLN | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 16.8 | 10.4 |
| Trailing P/E | 20.8 | 15.8 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.2% | 0.3% |
| EPS | 0.49 | 3.17 |
| Dividend Yield | 0.02% | 0.04% |